Participants in the study will be randomly assigned to receive either the combination of savolitinib and osimertinib or the chemotherapy treatment. The study will monitor the participants over a period to see how the cancer responds to the treatments. The researchers will look at how long the participants live without the cancer getting worse, which is known as progression-free survival. They will also assess overall survival, which is the length of time participants live after starting the study. The study will also evaluate the safety and side effects of the treatments, as well as how the treatments affect symptoms like shortness of breath, cough, and chest pain.

This trial is open-label, meaning both the participants and the researchers know which treatment is being given. The study will continue until 2027, and it aims to provide valuable information on the best treatment options for patients with advanced or metastatic NSCLC who have specific genetic changes and have progressed after previous treatment with osimertinib.

After a stroke is diagnosed, eligible individuals receive a single infusion of the assigned treatment shortly after the event. They remain in the hospital for a few days for close monitoring of any side effects and for basic health checks. Follow‑up visits are scheduled over the next three months to track recovery, including assessments of neurological function and overall health. The study collects information on any serious bleeding events, other adverse reactions, and measures of disability and functional outcome during this period.

The purpose is to find out how safe the medicines are and whether they can lower the activity of the cancer. Adults whose disease has returned after earlier therapy (relapsed) or does not respond to usual medicines (refractory) will receive the study drugs for several treatment cycles. Participants will have regular doctor visits, blood tests, and scans to watch for side effects and to see if the cancer shrinks. Terms like “biomarker‑selected” mean that a laboratory test is used to choose patients whose cancer has a specific characteristic; “dose limiting toxicity” describes side effects that stop the dose from being increased; and “overall response rate” is the percentage of patients whose cancer gets smaller or disappears.

The purpose of the study is to evaluate the effectiveness of selpercatinib in patients who have early-stage RET fusion-positive NSCLC and have already undergone surgery or radiation treatment. Participants in the study will be randomly assigned to receive either selpercatinib or a placebo. The study is designed to be double-blinded, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo during the trial.

Throughout the study, participants will be monitored to assess the progression of their condition and any potential side effects of the treatment. The trial aims to provide valuable information on whether selpercatinib can improve outcomes for patients with this specific type of lung cancer. The study is expected to continue for several years to gather comprehensive data on the treatment’s effectiveness and safety.

The purpose of this study is to determine if daily oral orforglipron is as effective as insulin glargine (an injectable insulin) in preventing major heart-related events in these patients. The study will look at outcomes such as myocardial infarction (heart attack), stroke, hospitalization for unstable angina (chest pain), and death related to heart disease.

This is a Phase 3, open-label study, which means participants and researchers will know which treatment is being given. Participants will either take orforglipron once daily by mouth or use insulin glargine injections while continuing their existing diabetes medications. The study will monitor their health status over time to compare the safety and effectiveness of these two treatment approaches.

The purpose of the study is to determine the safety and tolerability of these regimens in people with this condition. Participants are randomly assigned to receive either the active medication or the placebo, and neither the participants nor the study staff know which treatment is given. Over a period of several weeks, participants attend regular visits where vital signs, laboratory tests, and symptom questionnaires such as the MG-ADL (a simple survey that asks about daily activities affected by muscle weakness) are collected to monitor any side effects and changes in disease symptoms.

Participants are randomly assigned to receive either the new combination or the standard regimen; the new drugs are given by IV infusion on scheduled days while the oral pills are taken at home. The standard‑of‑care arm receives the physician‑chosen drugs (such as elotuzumab, carfilzomib or daratumumab) using the usual dosing routes. Throughout the study, blood work, imaging and a bone‑marrow test reviewed by an independent review committee (IRC) using criteria from the International Myeloma Working Group (IMWG) are performed to follow the disease. Additional outcomes include measures such as overall survival (OS), very good partial response (VGPR), overall response rate (ORR), time to first response (TTR), time to deepest response (TTBR) and duration of response (DOR). Safety is checked with standard grading systems from the NCI (CTCAE) and the ASTCT for side‑effects such as cytokine release syndrome (CRS), immune‑cell neurotoxicity (ICANS) and severe inflammation syndromes (HLH, IEC-HS). Patients also complete quality‑of‑life questionnaires from the EORTC (QLQ-MY20, QLQ-C30) and the FACTG tool, and report symptoms using the PRO-CTCAE system during regular visits until the disease progresses or the study ends.

During the study, participants will be monitored over a period of time to see how the medication affects the occurrence of major health events. These events include myocardial infarction, commonly known as a heart attack, stroke, or being hospitalized due to heart failure. The study also looks at coronary revascularization, which is a procedure used to improve blood flow to the heart, and any deaths caused by any reason.

Participants will receive a series of injections of either the study drug or the placebo over several months, with regular clinic visits for safety checks and simple breathing tests. One key breathing test measures the amount of air expelled in the first second of a forced breath, known as Forced Expiratory Volume in 1 second, to see how lung function changes. Throughout the study, people will complete questionnaires that assess health status and symptoms, such as the SGRQ-C (a quality‑of‑life survey), the CAAT (a symptom score), and the E-RS:COPD diary (records daily breathing problems). Researchers will also monitor for any side effects, using terms like TEAEs (any undesirable effects), AESIs (specific safety concerns), and SAEs (serious problems). Blood samples will be taken to check the drug level and to look for antidrug antibodies, which are the body’s immune response to the medication.

The purpose of the trial is to see whether adding the study drug to standard treatment leads to greater overall improvement in symptoms after six weeks. Volunteers are assigned to one of the two groups by chance in a double‑blind manner, meaning neither the participants nor the study staff know who receives the active substance. Over the six‑week period, participants will attend regular visits where simple questionnaires and brief health checks are completed to track changes in mood, anxiety, daily functioning, and overall quality of life. After the treatment phase, participants will have a final follow‑up visit to assess any lasting effects.

The aim of the study is to evaluate the safety and tolerability of long‑term use of this medication. Participants who have previously taken part in an earlier trial will continue to receive the inhaled powder and will be followed for up to two years. During this time they will attend regular clinic visits where simple checks such as blood tests, heart rhythm monitoring (ECG), measurement of oxygen use, and basic physical examinations are performed. The study also includes a group receiving placebo for comparison.

Throughout the study, participants will undergo a short walking test (6MWD) to see how far they can walk in six minutes, and lung function tests that measure the amount of air they can force out (FVC) and the speed of airflow (FEV1). Blood samples will be taken to check levels of a heart‑stress marker (NT-proBNP). These assessments help researchers understand how the medication affects breathing ability, heart strain, and overall health over the long term.

The purpose of the study is to see whether fenebrutinib can reduce the number of relapses more effectively than teriflunomide. It is a large, randomized trial where participants are assigned by chance to one of the treatment groups, and both the participants and the study staff are unaware of the assignments (double‑blind). The trial lasts about a year, during which safety and overall health are monitored.

During the study, participants will take a daily film‑coated tablet and attend regular visits that include a simple blood draw, a quick heart test called an ECG, and a brain scan using MRI. The MRI uses a special dye called gadolinium to highlight areas of activity and looks at both T1-weighted and T2-weighted images, which are just different ways the scanner shows the brain. The scan also measures changes in brain volume. In addition, participants will fill out a questionnaire called MSIS-29 about how the disease affects daily life, take a short mental speed test known as the SDMT, and have a blood test for a protein called neurofilament light chain that can signal nerve damage. All of these steps are designed to track how well the medicines work and whether they are safe.

The purpose of the study is to evaluate safety and find the best dose of the new medicines when used alone or in combination. Participants receive an IV infusion, which means the medicine is delivered directly into a vein, and they swallow tablets on a regular schedule. Treatment cycles are repeated every few weeks, and patients return to the clinic for regular check‑ups, blood tests, and simple examinations to watch for any side effects.

The main purpose of the study is to determine whether Enpatoran can lower skin disease activity. Participants will take the study medication daily for about 24 weeks and will attend regular clinic visits to check their skin and overall health. Skin severity will be measured with a tool called the CLASI, which gives a number based on how much of the skin is affected and how severe the rash is. Overall lupus activity may also be evaluated using the BICLA score. Safety will be monitored by recording any side effects, referred to as TEAEs. The study will finish after the 24‑week period, and the results will show whether the drug provided a meaningful improvement.

The purpose of the trial is to see if the additional antibiotic reduces the number of secondary infection episodes, including further episodes of sepsis, within 28 days. After enrollment, patients will continue their standard antibiotic treatment while receiving the study medication or placebo for up to seven days, followed by routine medical care and follow‑up visits to monitor health outcomes for the remainder of the month.

Participants will receive their assigned medicines on a regular schedule, with IV infusions given at the clinic and oral tablets taken at home. Throughout the study, doctors will perform routine checks, imaging scans, and questionnaires to monitor tumor size, side effects, and overall health. The trial continues until a predefined number of assessments are completed or until a participant stops treatment, after which follow‑up visits assess long‑term outcomes.

The main goal of the trial is to find out whether LY4268989 can bring more participants into clinical remission—periods when symptoms are absent or very mild—than the placebo during the first 10 weeks and to see if the benefit continues through a longer, 52‑week maintenance phase for those who respond early. Participants will start by taking the study tablets daily for about ten weeks (the induction phase). If they show improvement, they may continue the same treatment for up to a year (the maintenance phase), with regular visits to check how they are doing.

During the study, doctors will use a scoring system called the Modified Mayo Score to decide whether a person has reached remission; this score looks at stool frequency, bleeding, endoscopic findings, and overall health. “Induction” refers to the initial treatment period aimed at quickly reducing inflammation, while “maintenance” means the ongoing treatment intended to keep the disease under control. Participants will have routine check‑ups, blood tests, and questionnaires to monitor safety and how well the medication works.

In the study, treatment is given over a long period of time, and people are followed while they receive one of the study medicines. The study looks at how often a blood clot in a vein happens after treatment starts. The medicines being studied are baricitinib, adalimumab, and etanercept.

Participants in the study will be randomly assigned to one of the two treatment groups. The treatments will be given through an intravenous infusion, which means the medication is delivered directly into the bloodstream through a vein. The study will monitor how long patients live without their cancer getting worse, as well as their overall survival. The study will also look at how well the cancer responds to the treatment and how long any positive effects last.

The study aims to provide important information about the effectiveness of these treatment combinations for patients with advanced NSCLC. By comparing these treatments, researchers hope to find the best option for managing this type of lung cancer. The study will continue for several years to gather enough data to make informed conclusions about the treatments’ benefits and safety.

The trial will compare the effects of Clazakizumab with a placebo, which is a substance that looks like the medication but does not contain the active ingredient. The study will also use a saline solution, which is a simple saltwater solution, as part of the trial process. The purpose of the study is to determine the best dose of Clazakizumab that can effectively reduce inflammation and to assess its safety in patients with ESKD. Participants will receive the medication or placebo through an intravenous injection, which means it is given directly into a vein.

Throughout the study, researchers will monitor the participants’ health and track any changes in their condition. The study will also look at the impact of Clazakizumab on cardiovascular health, which refers to the health of the heart and blood vessels. This is important because patients with ESKD are at a higher risk of developing heart-related issues. The trial is designed to provide valuable information on how Clazakizumab can help manage inflammation and improve overall health outcomes for patients with ESKD undergoing dialysis.

The purpose is to determine whether the weekly treatment works at least as well as the daily treatment in promoting growth.

Participants will be assigned to receive either the weekly Somatrogon or the daily Genotropin for about twelve months. Their height will be measured regularly, and the main outcome will be the change in growth speed over the year, referred to as annualized height velocity. No additional procedures beyond the injections and height checks are required.

The purpose of the study is to evaluate whether Orelabrutinib can delay the worsening of disability compared with placebo. Participants will receive the assigned tablet each day for several years and will attend regular clinic visits where their ability to perform everyday tasks is checked and brain scans using MRI are performed to look for new lesions. The study will track how long it takes before a confirmed increase in disability occurs and will record any safety concerns throughout the trial.

During the study, volunteers will attend regular clinic visits over about 12 weeks. At each visit, doctors will check how the disease is doing using a scoring system called the Modified Mayo Score, which looks at symptoms, a visual exam of the colon (called an endoscopic exam), and lab results. A “clinical remission” means the person’s symptoms have become minimal or disappeared, while a “clinical response” means the symptoms have improved but may not be completely gone. An “endoscopic improvement” indicates that the lining of the colon looks better when viewed with a camera, and “histologic” improvement means that tissue samples show less inflammation under a microscope. Safety will be monitored by recording any side effects and noting if anyone stops the treatment because of them.

The purpose of the study is to determine whether Admilparant can be used safely over an extended period without causing serious side effects. Participants will take the medication each day and will attend regular visits where healthcare staff will check vital signs such as blood pressure and heart rate, review simple blood tests, and perform a basic heart test known as an ECG, which records the heart’s electrical activity. Any side effects that arise will be recorded and evaluated.

The study will continue for many months to gather enough information about safety and tolerability. Throughout the study, participants will be asked to report any new symptoms or problems, and they will receive routine medical check‑ups to monitor their overall health while using the medication.

The purpose of the study is to determine whether the drug can reduce skin thickness and be tolerated well over an extended period.

Participants will receive either the study medication or placebo by injection regularly for about one year and may continue for up to three years if they choose to stay in the extension phase. During the study, doctors will check the skin using a tool called the modified Rodnan Skin Score, which rates how tight the skin feels, and will perform a breathing test known as forced vital capacity to monitor lung function. Routine check‑ups will also include simple safety measurements such as blood tests, vital signs, and questions about any side effects.

The purpose of the study is to assess the safety and tolerability of these treatment regimens. Participants will receive a single injection at the start and then continue receiving additional injections according to a fixed schedule over many months. Regular visits will be scheduled to check health status, and an examination of the intestine using a camera (often called an endoscopy) will be performed around week 48 to see how the lining has responded.

Throughout the trial, researchers will closely watch for any side effects that arise after treatment and will record any new health problems. The endoscopic examination will help determine whether the inner surface of the colon shows signs of healing, providing an indication of how well the medication may be working while ensuring participants remain safe.

After the surgery, each person receives the assigned injection—either under the skin (subcutaneous) or into a muscle (intramuscular)—on a schedule set by the study team. Follow‑up visits are planned regularly to check health, monitor any side effects, and assess overall well‑being.

During the study, doctors will watch for any adverse events (unwanted health problems) and ask participants to complete questionnaires about their quality of life and daily functioning. This information helps determine if the treatment is safe and if it improves outcomes compared with the control injection.

The aim of the trial is to determine whether the combination of sarilumab and a 52‑week prednisone taper works better than prednisone taper alone in achieving lasting symptom control. Participants are randomly assigned to receive one of two dose levels of the study drug (150 mg or 200 mg) every two weeks, while all continue the steroid taper for one year, and they are followed for the same period to see how they respond.

Throughout the year, researchers check whether participants reach “remission,” meaning they have no significant pain or stiffness, and they record any side effects or laboratory changes. They also track how long remission lasts, whether symptoms return (a “flare”), and how the condition affects physical and mental well‑being using standard questionnaires. Safety is monitored continuously, and any serious problems are reported promptly.

Participants will be randomly assigned to receive either the active medication or the placebo for about one year, with regular clinic visits for injections and health checks. Blood samples will be taken to monitor liver enzymes (ALT and AST), a blood test called the ELF score that estimates liver scarring, and other measures such as cholesterol, blood sugar control (HbA1c), and body weight. Imaging tests, including a special ultrasound that measures liver stiffness (VCTE‑LSM), an MRI‑based scan (MRE), and an MRI that quantifies liver fat (MRI‑PDFF), will be performed at the start and at the end of the study to see how the liver is responding. Any side effects or abnormal lab results will be recorded throughout the study period.

The purpose of the trial is to determine whether MK-1045 can achieve a higher rate of complete remission (no detectable cancer) and improve overall survival (how long participants live) compared with blinatumomab. Participants will receive a series of treatment cycles lasting several weeks, during which doctors will monitor for adverse events (side effects) and check for minimal residual disease negativity (absence of tiny amounts of cancer cells). Some participants may later undergo allogeneic hematopoietic stem cell transplantation, a procedure that replaces diseased blood‑forming cells with healthy ones from a donor, if deemed appropriate by their physicians.

Participants will receive the assigned tablet daily and the infusion every few weeks, with regular clinic visits for safety checks, blood tests and imaging scans such as CT scans to look for changes in tumor size. The study will continue until the disease gets worse, a participant stops treatment, or the trial ends. Researchers will record how long the cancer stays stable (progression‑free survival), overall survival, side effects, and quality‑of‑life questionnaires.

The study compares two treatment approaches. One group receives a new drug identified as BV100 together with a low dose of polymyxin B, both given through an IV line. The other group receives the older antibiotic colistin combined with a higher dose of ampicillin/sulbactam, also by IV infusion. The purpose of the trial is to determine which combination works better and is safer for patients with this resistant infection. Participants are randomly assigned to one of the two groups, receive the medication for several days, and are then followed for about a month to see how they recover and to monitor any side effects.

The investigational treatment is an injectable form of efimosfermin alfa, given under the skin (subcutaneous injection). Participants are randomly assigned to receive either the study drug or a placebo, and neither the participants nor the study staff know which one is given (double‑blind). The study lasts about one year, with regular clinic visits for injections and safety checks.

The main goal is to see whether the drug can improve liver health by reducing inflammation and decreasing scarring (fibrosis) compared with the placebo. Researchers will look at changes in the liver tissue, blood tests, and overall health over the treatment period.

The purpose of the trial is to compare how well the new medicine works against the standard treatment in shrinking tumors and helping patients live longer. Participants will be randomly assigned to one of the two treatment arms and will receive the assigned therapy in repeated cycles every few weeks. Throughout the study, doctors will perform regular safety checks, blood tests, and imaging scans to see how the disease responds, and they will record any side effects that occur.

The purpose of the study is to find out whether the new medicine can improve breathing and reduce serious flare‑ups compared with the placebo. People who join will be randomly assigned to one of the two groups, and neither the participants nor the study staff will know which treatment each person receives (double‑blind). Over several months, participants will come to the clinic for routine visits where their lung function, symptoms and overall health will be checked.

During the study, participants will receive the injections at set intervals and will have simple breathing tests, such as measuring forced expiratory volume in one second (FEV1), which shows how much air can be exhaled quickly. They will also answer short questionnaires about how they feel, and will have basic safety checks like blood tests and a quick heart rhythm check (ECG). All of this information helps researchers see if the medicine works and is safe.

During the study, participants will be assigned to receive either depemokimab or a placebo through a subcutaneous injection, which is a shot given just under the skin. The study is designed so that neither the participants nor the researchers know which treatment is being administered. This approach helps ensure that the results are as accurate as possible.

The purpose of the study is to see if the new combination can keep the cancer from getting worse for a longer time than the standard treatments. Participants are randomly assigned to receive either the new three‑drug regimen or the standard therapy, and they take the medicines in repeated cycles while visiting the clinic for regular check‑ups and imaging scans. The main result being measured is progression‑free survival (PFS), which means the time until the cancer grows or the patient dies, and it is evaluated using standard imaging rules called RECIST and analyzed with the Kaplan‑Meier statistical method. Safety and side‑effects are recorded and graded according to the CTCAE system.